查看其它语言版本

MMJ PhytoTech Ltd

ASX:MMJ ISIN:AU000000MMJ4

Phytotech Medical ASX:PYL

MMJ PhytoTech Limited (ASX:MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through three business units, strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

MMJ has signed a definitive agreement with Canadian-based Harvest One Capital Corp. (CVE:WON.H) for the sale to Harvest One of 100% of the issued shares of United Greeneries Holdings Ltd and Satipharm AG.

United Greeneries Holding Ltd. has established world-class growing facilities in Canada, including the fully licensed Duncan Facility. MMJ is the first Australian-based company to receive a Canadian medicinal cannabis cultivation licence, and one of only a few companies globally with the capacity to commercially cultivate medicinal grade cannabis in a federally regulated environment.

The Company’s Swiss-based, medicinal products division operates under its 100% owned subsidiary, Satipharm AG, and is currently focused on developing regulatory compliant, unique oral delivery technologies that have the potential to deliver safe, effective and measured doses of medicinal cannabis to patients. MMJ began production of its first capsule product in May 2015, and is committed to providing novel treatment options throughout regulated markets globally.

PhytoTech Therapeutics Ltd is MMJ's Israel-based subsidiary responsible for the clinical research and development activities. In March 2016, PhytoTech Therapeutics completed a phase 1 clinical study which highlighted the safety and performance of Satipharm's capsule formulations in delivering CBD compounds to trial subjects.

     

新闻

澳交所首家药用大麻企业PhytoTech(ASX:PYL)本周挂牌

🕔1/20/2015 5:27:37 PM 3675

ACB News《澳华财经在线》报道,总部位于珀斯的Phytotech将于1月22日(周四)澳东时间11点开始交易,新股发行价为0.2澳元,IPO目标筹资额500万澳元,由于认购需求远高于拟定发行量,提前结束招股。

阅读全文
###

40,672 公司背景浏览

  • 本页浏览人次: (过去7日: 10) (过去30日: 48) (自发布以来: 10816) 

金融股市 ASX:MMJ

公司详细信息

    总部
  • Suite 25, 145 Stirling Highway
    Nedlands WA 6009
    Australia
  • 电话
  • +61-8-9389-3150 
  • 传真
  • +61-8-9389-3199 
  • 主要部门
  • 农业生物技术 
  • 支柱产业
  • 保健 
  • 主页
  • www.mmjphytotech.com.au
  • E:
  • info@mmjphytotech.com.au

财务报告

社会化媒体